Pharmacy First Expansion Proposed to Include Migraine Treatment, Aiming to Alleviate Healthcare Pressure
The Company Chemists’ Association (CCA) and Pfizer UK have proposed expanding the Pharmacy First program in England to include migraine treatment. This initiative aims to support over one million individuals suffering from acute headaches and migraines through community pharmacies. The report, published on May 20, 2026, suggests that this expansion could reduce the burden on other healthcare settings, provide faster access to care, and help patients return to work more quickly. Currently, Pharmacy First covers seven clinical pathways, including conditions like acute sore throat and sinusitis. The proposal highlights the potential for community pharmacies to play a more significant role in managing migraines, which account for millions of NHS appointments annually.